MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

A Phase IIa, Multicenter, Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine

A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.

Inclusion Criteria:

• Patient is 18 years of age or older
• Patient has had a history of migraine with or without aura
• Patient is able to complete study questionnaire(s) and paper diary

Exclusion Criteria:

• Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of the study
• Patient has basilar or hemiplegic migraine headache, hepatitis or psychiatric conditions
• Patient was older than 50 years of age at migraine onset
• History of gastric or small intestinal surgery or has a disease that causes malabsorption
• Patient has heart attack, unstable angina, coronary artery bypass surgery or other revascularization procedure, stroke, or transient ischemic attack 3 months before starting the study
• Currently participating or has participated in a study with an investigational compound or device within 30 days of starting the study
• Currently participating in a study with MK-0974 or MK-3207